"Major pharmaceutical partner is critical to realizing the full potential [Qsymia] franchise and build a market. To date, we have made good progress in this area," Zook, the new CEO of Vivus ", said during the company's second-quarter sales and earnings conference call with investors held on Tuesday evening.

Vivus developed promising weight-loss drug Qsymia and fruit plant weight loss capsules received permission to do a little more than a year ago by the U.S. Food and Drug Administration.

It was a disappointing start, however, and it was confirmed in its second-quarter financial. Although Qsymia prescriptions were up 37% quarter over quarter, they were transferred to a mere $ 5.5 million in sales, and Vivus spent $ 52.5 million during the quarter. All of these scenarios have been filled with its four certified mail-order pharmacies, onerous FDA, which has since been withdrawn.

Vivus recently experienced a rebellion of sorts, a difficult fight a proxy that was finally settled in favor of its 9.9% of the first investor in Manhattan FMC Corporation insisted on overthrowing the leadership and the creation of 11 new board members, including Zook, AstraZeneca PLC of the former leader, who successfully several fruit&plant usa commercial preparations. The new board has been carefully selected, FMC said to help provide the necessary expertise to perform the work. Only one of the four not-FMC selected board members, Marc Logan, has been appointed until April, when he began his FMC campaigner.